Key Points
- Director Casey Tansey purchased 35,572 Mobia Medical shares at an average price of $11.51, investing approximately $409,434 and increasing their ownership by 15.25% to 268,904 shares.
- Mobia Medical reported quarterly revenue of $13.51 million, up 102.4% year over year, but its adjusted loss of $1.10 per share missed analysts’ expectations of a $0.83 loss.
- Analyst sentiment remains broadly positive, with five Buy ratings, one Hold and one Sell; the consensus rating is Moderate Buy with an average price target of $20.75.
Mobia Medical, Inc. (NASDAQ:MOBI - Get Free Report) Director Casey Tansey bought 35,572 shares of the stock in a transaction dated Thursday, August 13th. The shares were purchased at an average cost of $11.51 per share, for a total transaction of $409,433.72. Following the completion of the purchase, the director owned 268,904 shares in the company, valued at approximately $3,095,085.04. This represents a 15.25% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Mobia Medical Stock Down 0.1%
NASDAQ:MOBI opened at $11.73 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.28 and a quick ratio of 12.80. Mobia Medical, Inc. has a 52 week low of $10.19 and a 52 week high of $15.29. The company's 50-day simple moving average is $12.40. The firm has a market cap of $390.49 million and a PE ratio of -0.61.
Mobia Medical (NASDAQ:MOBI - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.27). The company had revenue of $13.51 million during the quarter. The firm's revenue for the quarter was up 102.4% compared to the same quarter last year. Sell-side analysts expect that Mobia Medical, Inc. will post -2.76 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on MOBI. Weiss Ratings began coverage on Mobia Medical in a research report on Wednesday, August 12th. They set a "sell (e-)" rating on the stock. Zacks Research upgraded shares of Mobia Medical to a "hold" rating in a research report on Wednesday, June 3rd. BTIG Research reaffirmed a "buy" rating and set a $19.00 price objective on shares of Mobia Medical in a report on Wednesday, August 12th. Bank of America assumed coverage on shares of Mobia Medical in a research report on Tuesday, June 2nd. They issued a "buy" rating and a $16.00 target price on the stock. Finally, The Goldman Sachs Group began coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They set a "buy" rating and a $31.00 target price for the company. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Mobia Medical currently has a consensus rating of "Moderate Buy" and an average price target of $20.75.
Check Out Our Latest Research Report on MOBI
Mobia Medical Company Profile
(
Get Free Report)
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
